This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JNJ-1575

Johnson & Johnson

Drug Names(s): ALS-8176, ALS-008176, ALS8176

Description: ALS-8176 is an orally administered nucleoside analog that blocks the action of the RSV polymerase, resulting in antiviral activity against several commonly occurring RSV isolates including both the RSV A and B strains. RSV is a single-stranded, negative-RNA virus that has its own RNA-dependent RNA polymerase for genome replication.

Deal Structure: Alios and Johnson & Johnson
In September 2014, Johnson & Johnson announced a definitive agreement to acquire Alios BioPharma for approximately $1.75 billion in cash. In November 2014, Johnson & Johnson announced the completion of the acquisition of Alios BioPharma, Inc. for a total purchase price of approximately $1.75 billion in cash.


JNJ-1575 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug